Zymo Drug Kills Hep C Virus
ZymoGenetics (NASDAQ: ZGEN), a Seattle biotech company, and partner Bristol-Myers Squibb said today that a drug they are co-developing for hepatitis C was able to kill the virus with minimal side effects in a small four-week study. The trial looked at pegylated interferon lambda on its own, or in combination with a standard ribavirin treatment. The full data was presented at the European Association for the Study of the Liver meeting in Copenhagen, Denmark.
Trending on Xconomy
By posting a comment, you agree to our terms and conditions.